Effect van duurtraining en eiwit op spier en bloed Not applicable
Conditions
Interventions
Three times a week endurance training, for a total period of 12 weeks.
Each training session lasts approximately 60 minutes.
Group Intervention: protein supplement (30 g protein). After training and
Adaptation
Endurance
Muscle
Protein
Sponsors
Wageningen Universiteit
Eligibility
Age
18 Years to 64 Years
Inclusion criteria
Inclusion criteria: Male * Age between 18 and 30 years of age * BMI between 18.5 * 25 kg/m2 * VO2max 50 of lager * Recreationally active, performing sports on a non-competitive basis * Willing to give muscle biopsies * Willing to give blood samples * No use of antibiotics in the past month * No use of illicit drugs * Suitable veins for blood withdrawal * Registered by a general-practitioner * Consumption of alcohol beverages is less than 21 per week * No blood donor during the study * Able to be present and all university visits * Able to perform three exercise sessions weekly for 12 weeks * Not employed, or intern, or working on thesis at the department of Human Nutrition at Wageningen University * Not participating in another scientific study (except EetMeetWeet) * Able to participate during the experimental days en pre tests
Exclusion criteria
Exclusion criteria: * Medical condition that can interfere with the study outcome (i.e. cardiovascular disease, pulmonary disease, lactose and gluten intolerance) * Use of medications known to interfere with selected outcome measures (i.e. statins, fenofibrate) * Use of antithrombotic therapy (marcoumar, sintromitis, clopidogrel and NOAC*s). * Diagnosed with liver disease * Diagnosed diabetes mellitus type 1 or 2 * (Chronic) injuries of the locomotor system that can interfere with the intervention * Participants with a recent history or current state of COPD * Participants with a recent history or current state of rheumatoid arthritis * Participants with a recent history or current state of musculoskeletal/orthopedic disorders * Participants with a recent history or current state of renal disorder * Participants with a recent history or current state of cognitive impairment * Participants with orthopedic metal implants in the spine and/or upper/lower extremities * Participants with lactose intolerance and/or dairy protein allergy * Participants who are enrolled in an interventional biomedical research project or have received an investigational new drug or product with the last 30 days prior to screening. * Participants on medication, including anticoagulants
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| VO2max (maximal oxygen consumption during exercise) | — |
Secondary
| Measure | Time frame |
|---|---|
| Time trial (bicycle ergometer) 1RM strength (1RM leg press / Bio-dex) Quadriceps cross sectional area (MRI) Whole body and regional body composition (DXA-scan) Muscle fibre type specific distribution (muscle biopsy) Mitochondrial mass (muscle biopsy) Mitochondrial function (muscle biopsy) Haemoglobin mass (blood) Cardboxyhaemoglobin (blood) Haematocrit (blood) Red blood cell volume (blood) Plasma volume (blood) Body mass index (BMI) Waist circumference Leg volume | — |
Countries
The Netherlands
Outcome results
None listed